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INTRODUCTION 
"' "{\~'-';·'.! 
Since 19521 when Crigler and Najjar reported seven patients with 
"Congenital Familial NonheiQOlytic Jaundice (CFNJ) with Kernicterus"!( not 
described in previous literature, with the possible exception of Micheli 
and Dominici's patients reported in 1932:J there has been a continued 
interest in this disease entity, for its contribution toward the under-
standing of inborn errors of metabolis~ the metabolism of bilirubin, 
and the pathogenesis of kernicterus. To date, there are only twenty 
cases notable from the literature, and although much has been done toward 
---~ 
clarifying the etiology of this disease, not all aspects of its patho-
genesis are understood. In this p.aper, I shall attempt to summarize 
the present status regarding the Crigler-Najjar syndrome, CFNJ, and 
its relationship to bilirubin metabolism. 
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CLINICAL DESCRIPTION 
Crigler and Najjar classically described seven patients with jaun-
dice which appeared within the first three days after birth and persis-
1 
ted throughout life • The onset of jaundice was followed by a short period 
without any O·llher signs or symptoiiiS. Then, nonspecific symptoms of ano-
rexia, irritability or a mild infection set in. These were followed by 
symptoms of central nervous system disturbance (excepting one pat!ent}, 
which progressed till death, from two or three weeks up to slightly over 
one year thereafter. 
As is common experience when a new disease is described~patients 
involved show considerable homogeneity of signs and symptoms, subsequent 
reports show variat~ons of the original theme. The composite clinical 
findings are summarized in the following. 
Jaundice, consistent with the original description of the disease, 
has been found in all patients, and in all clearly recorded incidences, 
was noted in the first few days of life. Total serum bilirubin levels 
were about 15-25 mg/lOOml higher than that seen in "Gilbert's disease", 
with a range of 12.6 to 50.4. This hyperbilirubinemia in CFNJ patients 
persisted throughout their lifetime. 
There are no other signs or symptoms, except jaundice, for a variable 
period of time, prior to the development of the manifestation of central 
nervous system disturbance. In three cases, central nervous disturbances 
1, 3 
were manifested within the first week of life. In the majority of 
clearly recorded cases, signs snd symptoms of kernicterus set in within 
the first year after birth. These ranged from nonspecific symptoms of 
2 
3 
irritability, fever, anorexia, vomiting, sleeplessness to signs of distinct 
central nervous system disturbance: progressive spasticity, rigidity of the 
extrapyramidal type, opisthotonoid position, slurring of speech, intention tre-
1 4 5 
mar and even convulsions. ' ' Typically, the hands and arms showed frequent 
involuntary movements of the choreo-athetoid type, slow movements predomi-
6 
nating in the fingers and rapid ones in the proximal segments of the arms. 
The face might become immobile or the site of extensive uncoordinated acti-
1 
vity, Occasionally, slow writhing movements of the trunk were observed. 
1 3 
These neurological signs can be slowly or rapidly progressive to death. ' 
In the case of one patient, 
not appear until the age of 
signs of central nervous system disturbance did 
4 three years and the child died at the age of 
eleven and a half years, a few days after surgery for diaphragmatic hernia, 
unrelated to his underlying disease, 7 His neurological .status, however, was 
7 
noted to have deterioted post-operatively. Among the twenty patients known, 
1, 2, 3, 4, s, 6, 8, 9, 10 
at this writing, to be afflicted with this disease, six 
6,8,9,11,12 d h h 
survived beyond late childhood (five years), an t ree ave not yet 
11 12 developed any signs or symptoms of kernicterus. ' (See Table I) The 
ultimate prognosis of these three patients, however, must be highly guarded. 
I 
. 
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LABORATORY FINDINGS 
There has been no evidence of blood group incompatibility, except in 
one case where a mild degree of ABO erythroblastosis was noted. 3 Neither 
was there any evidence of hemolytic anemia, as shown by normal findings in 
saline osmotic fragility test, erythrocyte survival time, peripheral smear, 
hemoglobin, hematocrit, bone aarrow morphology and absence of splenomegaly. 
Low reticulocyte count has been reported uniformly, except in one patient, 
when reticulocyte count was 8X on one determination, but on subsequent deter-
3 
minations was found to be normal. 
Classical liver function tests, including bromsulphalein excretion, 
cephalin flocculation, thymol turbidity, and alkaline phosphatase, were all 
within normal limits. Although renal hippuric acid excretion was noted as 
subnormal after oral sodium benzoate ingestion in one patient. 4 The results 
of this test were subsequently found to be within normal limits following 
9 intravenous sodium benzoate administration. 
Normal unobstructed extrahepatic biliary tract was also demonstrated by 
4 9 intravenous cholangiograms in two cases ' and by operative cholangiogram 
in a third patient.5 Further evidence for nonobstructive jaundice was ob-
4 5 9 tained by findings of patent biliary tree at laparOtomy in the same patients. ' ' 
There was no bilirubin in the urine, with one exception. 3 Urine color 
1,4,5,6,8,9 
was variously noted to be normal, light amber, to golden yellow, 
and in four cases the color was noted to be significantly different from 
that of normal urine. 9 The nature of the pigments causing this abnormal 
coloration was unknown, although they were noted to show similarities to 
those present in plasma and urine of hepatectomized dogs. 9 It has been 
noted that nonbilirubin pigments in plasma obtained under conditions of 
sustained jaundice, might represent dipyrDi end products of bilirubin de-
13 generation in the tissues, 
Stool examination revealed presence 0f bile and normal values for fecal 
urobilin excretion, according to Crigler- and_:Najjar' s original report on this 
1 14 disease. These results were obtained, however, by a method not in common 
use, as noted by Schmid. 9 Later determinat-ions for fecal urobilinogen ex-
cretio~found it to be very low, ranging from 0,23 mg/24 hours (two years 
9 5 9 
old), to 5 mg/24 hours (two years old and seveR years old ), in spite of 
serum bilirubin concentrations greater than 20 mg/lOOml in all cases. Fur-
thermore, in one child, J:J>.H •• reported by Crigler and Najjar as having 
1 
normal urobilin excretion, fecal urobilinogen excretion was subsequently 
9 
found to be 1.4 mg/24 hours. At the present time, one cannot say whether 
this represents a definite reduction in fecal urobilinogen excretion, because 
there are not enough data on normal fecal pigment excretion in the age group 
9 
under consideration. Unlike patients with complete 
stool color was normal, ranging from brown to yellow 
biliary obstruction, 
3 5 15 
orange. ' ' 
Bile from the gall bladder and duodenum was studied in six cases. Direct 
and indirect reacting bilirubin were found in varying proportions. In three 
cases, when duodenal bile was obtained before and after stimulation with 
Decholin or magnesium sulfate, the specimens had a faint lemon juice color 
and total bilirubin ranged from 0.1-1.5 mg/100ml1 with essentially all of 
9 15 the pigment in the indirect reacting form. ' In the fourth case, R.S., 
the duodenal bile, obtained similarly, contained 4 mg/lOOml.of total bilirubin, 
9 with about one half in the direct reacting form, Bile collected directly from 
the gall bladder at laparotomy on the same patient contained 70 mg/lOOml 
of total bilirubin, with about one third in the form of glucuronide, In a 
6 
fifth case, w., where bile was also obtained from the gall bladder at lapa-
rotomy, the color was noted to be dark green, containing 18 ~/lOOml of direct 
reacting bilirubin by the van den Bergh reaction and 35 mg/lOOml of total 
bilirubin. 5 Lastly, bile aspirated in a sixth patient, J., contained vir-
tually only direct reacting bilirubin. 16 
As mentioned earlier, the total serum bilirubin ranged from 12.6-50.4 
mg/lOOml. The increase of total serum bilirubin was due mainly to the ele-
vation in the indirect reacting type. Direct serum bilirubin was usually not 
present or negligible, neyer reaching J 1 concentration above 2 mg/lOOml. 
Paper chromatographic studies of the aEo derivatives of serum bilirubin on 
three patients, J.D., J.D.H., J.W'., showed presence of non-conjugated bili-
rubin only, without any evidence of bilirubin gluduronide. 15 Bilirubin re-
tention was measured spectrophotometrically, by intravenous infusion of 5 
mg/kg body weight of commercial bilirubin (crystalline form) dissolved in 
0.1 M sterile sodium carbonate. 17 In two patients, J.D.H., L.T., bilirubin 
retention was 40 and 26l at fifteen weeks of age, while a normal control 
1 infant of the same age showed Sl retention. 
Studies on the chemical nature of the bile pigments in sera of Crigler-
Najjar patients include isolation and crystallization of the pigment. The 
crystalline bilirubin so isolated had an absorption spectrum same as that of 
indirectcreacting bilirubin from patients with other types of jaundice and 
1 4 
moved with the albumin fraction as seen on paper electrophoresis (pH 8.6). ' 
In order to determine if the hyperbilirubinemia might be due to an 
abnormal form of bilirubin, which could not be adequately excreted by the 
liver, one patient's (J.D.) plasma was infused into a non-jaundiced recipient. 
Determinat~ons of bilirubin concentration in serum were done on the recipient 
at intervals after infusion. Within two and a half hours after infusion, the 
7 
recipient's serum bilirubin concentration had returned to the pre-infusion 
value. 4 
9 
HISTOLOGICAL FINDINGS 
Out of the twenty cases of known CFNJ patients, liver tissue was his-
tologically evaluated in fourteen cases; reports of findings on the brain and 
other organs were available in only three~;,.\E_~:_:he_::~~~---au~~­
'performe~. There were no significant abnormalities noted in the liver and 
the pathological findings were primarily limited to the brain, 
Microscopic examination of liver tissue from Crig~er and Najjar's ori-
1 a.!, .. ,...,._J.. .. 
ginal patients showed no obvious histologic changes, 'The only'\ finding was 
the presence of bile thrombi in the hepatic canaliculi, and it was noted that 
the degree of this abnormality varied and was not relsted to the duration or 
degree of jaundice. In one child, J.D.H., bile thrombi were also noted in 
the hepatic ducts and in three other children, L.M., L.T., J.J.T., slight 
periportal fibrosis was observed in some areas, although the fibrosis was 
far from being diffuse, 1 Subsequently microscopic evaluations of liver tissue, 
either by biopsy or at autopsy, were uniformly reported as normal in appear-
ance. 4, 6, s, 9 
The major pathology in patients with this'disease was found in the 
18 
brain and considered to be consistent with the diagnosis of kernicterus. 
The brains examined (J.R.H., J., R,M,B.) were stained markedly yellow. 
Pathologic lesions, varying from fat droplets in the nerve cell to actual loss 
' ' 
of nerve cell, were seen in the basal ganglia, subthalamic nuclei, cerebellum, 
hippocampus, quadrigeminal bodies, and cerebral cortex. 1• 3• 6 
REVIEW OF BILIRUBIN METABOLISM 
In order to facilitate the understanding and interpretation of the 
defect and pathogenesis in the CFNJ patients, I shall try to summarize 
the physiology of bilirubin metabolism, emphasizing some of the recent 
developments and the phases which are most pertinent to the CFNJ patient. 
I. Sources of Bilirubin : 
The principal source of bilirubin is derived from the normal daily 
destruction of red cells with concomitant degradation of about one per 
cent of the total hemoglobin mass per d~. It is estimated that this 
accounts for 70-90% of the bilirubin formed.l9,20 In adults hemoglobin 
is transported in the plasma in the form of a conplex with haptoglobin.) 1 
proteins whi~ have a specifin affinity for hemoglobin?1 In most newborns, 
however, it is found that this transport mechanism is lacking.21 
The precise sequence of events invQved in the degradation of hemoglobin 
is uncertain. The pathway for hemoglobin degradation which is more widely 
accepted today involves the oxidative removal of the carbon atom in the 
alpha-methene bridge which opens the porphyrin ring to yield choleglobin. 
By subsequent removal of iron and globin, choleglobin is converted to 
10 
biliverdin which, on reduction of its central methene bond, gives bilirubin.22, 23 
That this process of red cell degradation to give bilirubin occurs in the 
reticulo-endothelial syste~is still generally held to be true, although it 
was thought that hemoglobin degradation might begin in intact senescent 
red cells before they were taken up and destroyed by the reticulo-endothelial 
system.23 More recently, experiments using labelled red blood cell, 
hemoglobin in rats, suggested that the metabolic disposition of intracorpus-
cular hemoglobin and of unbound plasma hemoglobin may differ from that of 
the hemoglobin-haptoglobin complex.24 
Assuming that there is a quantitative conversion of hemoglobin to 
bilirubin, one gram of the former yields approximately 34 mgms. of the 
latter. In a t-hree kg . inf~t •. >dtJt.l9.Q....\l!J. .. l2J&9~Ume,total hemoglobin 
~ q ,., J -~  ,;.)---~., 
mass of 54 g, ~.5g hemoglobin 17 lllg bilirubi!ifis destroyed\daily.25 
-------.... ~...... ~ 
In the light of this continuous breakdown of hemoglobin, serum bilirubin 
is expected to accumulate continuously, if it were not excreted. The serum 
bilirubin level in the CFNJ patients, however, is maintained at a steady, 
though elevated level. 
Recent studies infusing labelled cl4 and Fl9 erythrocytes, hemoglobin 
and bilirubin into rats (Sprague-Dawley) with bile fistula and measuring 
labelled bilirubin in the bile and urine, showed that 20-45% of the admin-
istered heme-c14 was not recovered as bilirubin-c14. 24 Urinary loss of 
heme pigment never exceeded 4% and although tissue retention was not ruled 
out, the excmtion of unlabelled bilirubin, derived from endogenous.erythro-
cytes, continued unabated. These~~dl~ {o the finding that injected 
bilirubin-c14 led to 90% recovery in the bile, would seem to favor the 
contention that there are alternate pathways which convert heme-cl4 to 
excretory products other than bilirubin.24 
Dipyrrolic compounds, such as mesobilifuscin and propentdyopent, 
11 
thought earlier to be normally occurring excretory product of heme metabolism,9 
were considered to be unlikely as the non-bilirubin excretory products 
postulated above,24 and their identity remained unestablished. That the 
intravenously injected bilirubin-c14 was 90% recovered in the bile would 
indicate that the postulated non- bilirubin excretory products may only be 
derived from heme or perhaps from bilirubin wi tl\.j.n the reticulo-endothelial 
system, but cannot be formed from bilirubin in the circulation,24 
One would, however, be interested to know the amount of fecal bilirubin 
loss in the above experiments, which were not reported, especially in the 
12 
light of some recent findings on the transfer of conjugated and unconjugated 
bilirubin across the intestinal lumen and subsequent excretion in the stool,26.27 
~l. 
There are other precursors of bilirubin, among these is methemalbumin, 
formed by attachment of the prostheti9heme group of hemoglobin to albumin,22, 
28,29,30 Since this pigment binds albumin, it can compete with bilirubin 
for binding sites and drive the latter into tissues, thus increasing the 
likelihood of kernicterus,25 This will be discussed in greater detail later. 
Several sources of bilirubin other than the hemoglobin of circulating 
erythrocytes have been suggested by Londonl9 and Gray20 and their associates 
which include: 1) heme formed in excess of globin during hemoglobin 
synthesis; 2) intracorpuscular degradation of hemoglobin during the maturation 
of the early erythrocyte in bone marrow; J) destruction of newly formed 
erythrocytes in the bone marrow before they reach the circulation; 4) direct 
s,nthesis from a metabolic pool of pyrroles; 5) other heme proteins such 
as myoglobin, catalase, and the cytochromes. In vitro studies demonstrated 
formation of bile pigments on coupled oxidation of ascorbic acid and myoglobin, 
catalase, and peroxidase, although not with cytochrome- c,Jl 
II. Transport of Bilirubin in Plasma: 
The exact mechanism by which bilirubin is released from the reticulo-
endothelial system into the plasma is not clear. The pigment is virtually 
insoluble in water or bloodl2 and must be carried in plasma by attachment to 
proteins. It is general~ agreed that in jaundiced serums most of the 
bilirubin is bound to albumin}] forming a relatively stable complex. 34 
Albumin seems to bind bilirubin preferential~ in plasma,39 but other 
proteins are capable of binding bilirubin.34 Among these is the alpha1-
globulin of fraction V-1,35 estimated to constitute less than 0.1% of all 
plasma proteins and regarded as the most stable specific bilirubin-binding 
plasma protein, 36 
The linkage between bilirubin and albumin is considered sufficient~ 
stable to prevent bilirubin from passing through semipermeable membrane at 
13 
normal conditions,37 The binding can be uncoupled by certain organ~c anions,38 
and by lowering the serum pH below 5,o,39 
Most of the studies on protein binding of bilirubin in serum were done 
on icteric serum or with bilirubin added to serum,9 That under these condi-
tions bilirubin is preferential~ bound to albumin does not necessarily 
indicate that albumin is also the pril::ipal carrier of bilirubin under 
physiologic· conditions of much lower serum bilirubin content,9 Norma~ the 
serum bilirubin concentration lies between 0,5 and 1.0 mg/lOOml, though the 
precise upper limit is difficult to define,40 
III.Biosythesis of Bilirubin Glucuronide: 
The individual steps for the biosynthesis of bilirubin glucuronide may 
be visualized as follows: 1) transport of bilirubin from the plasma across 
the liver cell membrane facing the sinusoids; 2) conjugation by the 
microsomal enzyme system; 3) excretion of conjugated bilirubin across the 
liver cell membrane facing the cani.iculi as bile. (See diagram on following 
I shall however discuss uptake and excretion of bilirubin first 
before I consider the topic of conjugation, 
~! 
LiveY c~rr 
A. Hepatic Uptake and wretion of Bilirubin: There is a period of 
del~ between uptake and excretion which appears to depend partly on bilirubin 
conjugation, and during this del~ the bilirubin is stored in the liver,42 
Rate and effectiveness of conjugating: mechanism affect the rate of uptake 
and excretion,42,43 It is suggested that an active transport s~stem ~ be 
required for movement ,of bilirubin froa the cell membrane facing the siriusoids, 
to the microsomes for conjugation and then to the cell~embrane facing the 
canaliculi for excretion,40 This contention is supported by Hanzon's direct 
microscopic studies on uranium excretion, which demonstrated that bilirubin 
diffuses passively through the sinusoidal endothelial cells, is concentrated 
close to the endothelial surface of the liver cell b.1 an active process, 
diffuses passively across the celL as a consequence of the concentration 
gradi~t developed, is then actively concentrated a second time close to the 
canalicular surface, ultimately to be excreted in the bile,44 This author 
stressed the unidirectional nature of the preceding process and also 
demonstrated that hepatocellular injury or biliary obstruction can reverse 
the cell polarity, pel'lllitting bilirubin to go from the canaliculus to the 
sinusoid. 
The excretion of bilirubin was shown to be proportional to the square 
of its plasma concentration,l7 and that there is a limitto the excretion 
capacity of the liver which when exceeded leads to progressive rise in 
serum bilirubin level.45,46 Furthermore, it is believed that the limiting 
factor in the metabolism of bilirubin is not the ability to conjugate but 
probably involves either the uptake of bilirubin from plasma or the ability 
to excrete the conjugated product.42 
B. Conjugation of Bilirubin: The conjugation of bilirubin in liver 
has been demonstrated by studies using liver preparations from man and 
various animals,l6,46-48 and ahown to involve a series of enzymatic steps, 
terminating in the enzyme transfer of glucuronic acid (GA) from uridine 
diphosphate glucuronic acid (UDPGA) to bi.Lirubin, 4Ba as outlined belows:ci: 
l. ATP + UDP Nucleosi@ Diphospho!Q.nase UTP + ADP 
(Uridine Diphosphate) (Uridine Triphosphate) 
2. UTP + G-1-P UDPG Pyrgphosphorylase UDPG t- PP 
(Glucose-1-Phosphate) (Uridine Diphosphate Glucose) 
3. UDPG + 2DPN UDFG De~ogenase UDPGA+ 2DPNH t 2H 
(in soluble 1vel extract) 
15 
4. UDPGA+ Bilirubin Glucpl Transferase Bili.OO + UDP 
(in crosafues) (Bilirubin Diglucuronide) 
The enzyme glucuronTl transferase which accomplishes the transfer is located 
in the microsomes of the liver cells.46,47,49-51 
Aside from the bilirubin diglucuronide, indicated above, an intermediary 
pigment bilirubin monoglucuro~de is also found in man.52 The exacb role of 
the formation of bilirubin monoglucuronide in bilirubin metabolism is not 
fully understood. Findings of Hoffman et al 53 suggested that bilirubin 
monoglucuronide might be found extrabepatically or prehepatically which 
might precede or perhaps facilitate the intrahepatic formation of diglucuronide.53 
16 
The extent to which this is done under normal circumstances in man has not 
been determined. Bilirubin monoglucuronide was not found in infants with 
physiological jaundice,54 but was demonstrated along with bilirubin diglucu-
ronide by solvent partition technique in serum of infants with erythroblastosis 
and hepatitis.55 It is also thought that the toxicity of bilirubin monoglu-
curonide to tissues is less than that of unconjugated bilirubin on the basis 
of solubility characteristics.55 More recently, sj;udies using the preceding 
technique indicate that there is variability i-Pc:pacity of premature infants 
to form bilirubin monoglucuronide and diglucuronide.56 In the smaller 
premature and hypoxic infants studied, the formation of monoglucuronide 
gJ 56 
seems to be decreased. 
The preponderance of evidence suggests that themajo) and perhap!ithe 
so1,mechanism for glucuronide conjugation is the precedin~described 
process, and that glucuronic acid can not be used directly for glucuronide 
formation.49,50 That after administration of labelled glucuronic aci~'a 
small fraction of the labeliia may appear~n the glucuronides excrete~in 
the urine,57 is probab~explained by the observation that glucuronic acid 
is an intermediate in one of the glycolytic pathways. 58 Thuj [he administere~ 
labelled glucuronide :Which:j,s··partbily' absorbed and ·metab91ized, may appear 
) 
in various carbohydrate fractions, one of which appears in that necessary 
for glucuronidation. 
That the bilirubin may be conjugated directly with glucuronic acid by 
an alternative pathway has been suggested, however. In vivo the rate of 
glucuronide for~t~~::.~-~-foun~r:'De augmented by administr::ion of 
glucuronic acid~ Danof~- =~-~.~- ~ Moreover, Brown et al found that 
------···------- ' . 
liver homogenates of newborn guinea pigs deficient in glucuronYl transferase 
were capable of conjugating o-aminophenol when ATP and glucuronic acid, 
sodium glucuronate or glucuronolactone was added, These authors suggested 
that the glucuronic acid might enhance the activity of uridine diphosphate 
glucuronic acid - glucuronyl transferase system by inhibiting beta-glucuron-
idase, found in high concentration in the newborn and known to decrease the 
conjugation of o-aminophenol. Hsia61 gave labelled sodium glucuronate and 
17 
glucurono lactone to dogs but found no evidence of conjugation with bilirubin. 
Brown et al's interpretation is further refuted by the finding that 4-methyl-
umbelliferone was conjugated with glucuronic acid when incubated with ATP, 
UTP, and a soluble fraction of rat liver homogenate in the absence of glucu-
ronyl transferase,62 But this latter finding was considered as evidence 
supporting an alternate pathway of glucuronide conjugation,62 Whether or 
not an alternate glucuronidation pathway exists in vivo remains to be 
determined. 
It is also not known whether a single or several related microsomal 
enzymes are involved in the conjugation of bilirubin and other aglycones. 63 
f "~I. f~,.. ....,_ 
TAe ~ieu~~ects for and against the ~ontention that several, instead of 
IS 
one, specific acting enzyme may exist aPe discussed under the etiology of 
this disease. 
Isselbacher and Ma_Carthy observed that not all of the direct reacting 
bilirubin is conjugated with glucuronid/!4 Approximately 15:l\ of the direct 
reacting bilirubin pigment in human bile is conjugated as sulfate. The 
synthesis of bilirubin sulfate involves the transfer of sulfate from active 
sulfate to bilirubin by· an enzyme, sulfate transferase,found in the soluble 
fraction of rat liver homogenates. 
These authors also observed that an additional 9% of bile pigment, which 
gives a direct van den Bergh reaction in human bile is conjugated with 
neither glucuronic acid aor sulfate. These other conjugates may be of methyl 
or glycine radicles.64 
In addition to liver, other tissues have been reported to 
·1--f'T\D 
have ability 
to form glucuronide in vitro, including kidney5J,65 gastrointestinal tract,53 
especially the mucosa of the upper gastrointestinal tract,65 and even the 
brain.48 Glucuronyl transferase was also demonstrated in serum of animals 
and humans with hepatic necrosis.62,40 It was noted, however, that reductibn 
of hepatic transferase activity following liver damage results from a loss 
of enzyme-containing microsomes rather than from a reduction in their 
enzyme content,6~ ·which raises the question of whether the demonstrated 
serum transferase activity was due to circulating microsomes or to presence 
of the enzyme in some solubilized form. In vivo studies have demonstrated 
that Pigment I may be formed in hepatomized, nephrectomized and even complete 
eviserated animals.5J, 67 In none of these experiments was it established 
that Pigment I was bilirubin monoglucuronide.4° Furthermore it is believed 
that extrahepatic conjugation of bilirubin in vivo is probably of little 
physiological significance.9 
In the newborn period, during which the onset of jaundice of CFNJ 
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patients occur, it has been established that several of the terminal enzyme 
reactions involved in glucuronide conjugation are relatively deficient.46,68,69 
The newborn liver in man has much less glucuronyl transferase activity than 
does the liver of the adult and there is gradual development of this function 
over the first few weeks of life.69 It is thought that this relatively low 
activity of glucuronyl transferase is the basis for accumulation of unconju-
gated bilirubin in the neonatal period. 25,70 Uridine diphosphate glucuronic 
acid is however also decreased in the newborn liver. This is in part 
accounted for by the limited activity of UDPG dehydrogenase. 69 The syn-
thesis 
ronide 
of UDP~ is believed not to be the rate limiting step in glucu-
71 formation. 
The developmen1ilcapacity for glucuronide conjugation has been found to 
be different in different organs. Capacity for glucuronide synthesis in 
the liver and kidney increases slowly in the newborn period, beginning 
shortly before birth and continuing for several days and even weeks after 
birth.68 The capacity for glucuronide synthesis in gastrointestinal tis-
sue, however, decreases after birth, and fetal gastrointestinal mucosa 
demonstrates more activity of an enzyme which is similar, if not identical 
with, glucuronyl transferase, as compared to gastrointestinal mucosa of 
the adult anima1.68 
v. Fate of Bilirubin: 
On reaching the intestinal tract, conjugated bilirubin is converted 
by bacteria to urobilinogens.72 To a variable degree, these are then oxi-
dized to urobilins, the precise mechanism of this oxidation is uncertain. 
The actual conversion of bilirubin to urobilinogen is believed to 
occur in the colon.73 Some of this urobilinogen is reabsorbed and returned 
to the liver ultimately to be re-excreted in the bile,72 or excreted in 
the urine. 
The possibility that some bilirubin is reabsorbed in the small in-
testine prior to its reduction to urobilinogen was suggested by early 
observations that oral administration of bilirubin in dogs led to an in-
crease in its excretion in the bile.74 The question of enterohepatic 
19 
circulation has been studied recentl~by intraduodenal administration 
of labelled bilirubin-cl4 in normal rats and man, and in rats and man 
with CFNJ, 26,75 l0-30% of either conjugated or unconjugated bilirubin-cl4 
infused into the duodenum was recovered in the bile fistulae of normal 
rats as conjugated bilirubin-cl4,75 This was confirmed by similar studies 
jaundiced 
in mildly icteric, but- Gltherwise normal, human,/ : rats (Gunn strain) and 
human (J,d 1E.) with CFNJ which revealed that total intestinal absorption 
approximated 15% of free or conjugated bilirubin administered into the 
duodenum. 26 Moreover, irrespective of free or conjugated bilirubin-c14 
given in the duodenum, there was significant elevation of unconjugated 
serum bilirubin-cl4, and in Gunn rats, virtually no bilirubin-cl4 was 
recovered in bile, if conjugated bilirubin-cl4 was administered into the 
duodenum.26 These studies indicate that little, if any, conjugated bili-
rubin is absorbed unaltered, and that a significant fraction is hydrolyzed 
and absorbed as unconjugated bilirubin,26 
~aundiced rats 
In similar experiments in man (J,d1 !:., ) with CFNJ imd F ; , J.t has 
been found that unconjugated bilirubin is transferred directly acros~~e 
mucosa into the intestine27 whereas conjugated bilirubin is believed
4
to be 
~t excreted via the gastrointestinal mucosa.78 These studies also demon-
strated that derivatives of labelled bilirubin are excreted in bile, in 
stool uncontaminated with bile, and to a lesser extent in urine,27 This 
may explain ~r the plasma bilirubin levels in patients with CFNJ, to be 
discussed later. It is thus apparent that, at least in Gunn rats and in 
man with CFNJ or Crigler-Najjar syndrome, the gut contains a bilirubin 
pool which exchanges across the intestinal mucosa with the plasma pool.77 
If it is assumed that the degradation of hemoglobin from senescent 
20 
erythrocyt~entails its ultimate quantitative conversion to urobilinogen, 
the amount of pigment actual~ recovered in the urine and feces falls: short 
of that expected,40 This descrepancy, yet to be resolved, is closely related 
to the finding that patients with CFNJ are able to maintain a steady plasma 
bilirubin level despite continued pigment production, which will be discussed 
in greater detail under the etiology of this disease. 
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In this summary of bilirubin metabolism, I have alluded to some of the 
unsettled problems and the recent developments of interest, including the 
findings on bilirubin absorption and excretion in the gastrointestinal tract; 
alternate pathw~s for glucuronidation; pathways of bilirubin conjugation not 
involving glucuronidation; pathways for converting hemoglobin to non bilirubin 
excretory products. These are precisely the same problems, the elucidation 
of which will give a better understanding of CFNJ. I shall therefore make 
reference to them again in the discussion of the etiology of this disease. 
THE VAN DEN BERGH TEST FOR BILIRUBIN 
In 1916 van den Bergh and MUller ?9 introduced the Ehrlich-Proescher 
bilirubin-diazo reaction for use in clinical medicine. Since then the van 
den Bergh test has been the major test used to measure conjugated and 
unconjugated bilirubin levels. Because of its empirical nature,however, its 
accuracy as a measurement of conjugated and unconjugated bilirubin has been 
questioned. It is thus desirable to elucidate the advantages and shortcomings 
in using this test. Moreover, such an elucidation is necessary for the 
evaluation of bilirubin levels in the CFNJ patients which are mostly 
measured by the van den Bergh test, and in the experimental work utilizing 
this test. 
Van den Bergh and Muller classically described a direct and an indirect 
reacting bilirubin with diazotized sulfanilic acid reagent, the former 
reacting immediately with the reagent in aqueous solution, whereas, the 
latter required addition of alcohol for reaction. This difference in 
bilirubin reaction was accounted for qy various theories, but the conclusive 
work was done by Cole and Lathe80 in 1953 when they separated indirect and 
direct bilirubin by reverse-phase partition chromatography. The indirect 
reacting pigment which was soluble in organic solvents, was shown to be 
indentical with crystalline bilirubin, while the direct reacting pigment 
proved to be water"solubleat acid pH.The direct reacting pigment was 
subsequently partitioned to yield twc fractions, both water soluble and 
thus reacted di~ectly in the van den Bergh test in aqueous solution. These 
. BOa fractions were designated Pigment I and P~gment II. The direct reacting 
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Pigment! and II and the indirectreacting bilirubin were subsequently indentified 
to be bilirubin conjugated with one molecule of glucuronide, with two 
molecules of glucuronide and who2lyuncon~ugated bilirubin, respectively.52, 
8l, 8J-85 Despite the finding that ethanol was necessary for the complete 
coupling of Pigment I eluted from kieselguhr columns, 81 it was demonstrated 
23 
. bilirubin .~· ·· 
later that, at least in plasma, /' • •.monogl.ucuronide coupled completely in "'!'7;;.;> 
82 bilirubin 
absence of ethanol. One author, however, still thinks that / .. monoglucuronide 
is measured with the total bilirubin rather than with the one-minute 
"direct" fraction. 25 
Not all the bile pigments which give the direct van den Bergh reaction 
are glucuronides. 81 As mentioned earlier, the nonglucuronide fraction 
constituted 24% of total azopigment derivative of bilirubin in human bile, 
with about 14% in sulfate form and the remaining 9-10% possibly conjugated 
with carboxyl-linked methyl or glycine radicals. 64 With and Schmid also 
found that a: smal.L·f:i:laction· of'cuncolljtigated pigment in plasma reacted with 
the van den Bergh diazo reagent in the absence of alcohol,3J,B6 and thought 
that this fraction was due to the presence of solubilizing substances such 
as bile acids, urea, and citrate.33 
In addition to the preceding findings which throw some doubt on the 
exactness of the van den Bergh reaction as a measurement of the concentration 
of conjugated and unconjugated bilirubin, 86 other factors can affect the 
results of the test. These factors include the time allowed for coupling~7 
the concentration of unconj.ugated bilirubin~8 the pH, the protein concentration, 
and the amount of diazotizea sUlfanilic acid used. 89 Some uncertainty still 
exists regarding the optimal time for the coupling. 11espite the various 
shortcomings, the van den· Bergh test.is still widely used and is believed 
to provide a reasonable approximation of the total amount of conjugated 
bilirubin determined by the chromatographic methods, 90which are yet too 
cumbersome for routine clinical use. 
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ETIOLOGY 
A brief review of the clinical and laboratory findings of CFNJ 
patients will show that this disease is non-hemolytic, non-infectious, 
and non-obstructive, and that it is probably attributable to failure 
of conjugation of bilirubin: 
(1) There is no hematologic or biochemical evidence of in-
creased hemolysis. 
(2) There is no evidence for obstruction. 
(3) Classical liver function tests are all within normal 
limits. The only abnormality found is a prolonged retention of ad-
1 
ministered crystalline bilirubin. 
(4) Serum from patients with CFNJ infused into human control 
4 
showed normal rate of elimination. 
(5} Liver histology shows no significant abnormality. 
(6) Paper chromatographic techniques have conclusively shown 15 
that the only pigment in the serum is unconjugated. Those who have re-
ported the presence of very small amounts of conjugated pigment have all 
used the diazo method which is only an approximation, discussed earlier. 
(7} No conjugated bilirubin has been found in the bile of 
patients with CFNJ excepting three ca,ses. In these three cases, J., R.S., 
5, 9, 16 w., direct bilirubin was found, but as was pointed out previously, 
presence of solubilizing substances such as bile acids, urea, and citrate 
33 
will lead to a direct diazo reaction. The·ptesence of these substances 
has not been ruled out. 
Therefore most experimental work has concentrated on the inability of 
the patients to form glucuronides of different substrates. 
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I. Studies on Patients, in Vivo 
A. Steroid Conjugation: It is known generally that the numerous corti-
,yJ---. 
costeroids and 17-ketosteroid metabolites appearing in the urine is con-
jugated with glucuronic acid. Isselbacher and Axelrod demonstrated that 
glucuronides of tetrahydrocortisone, a major metabolite of hydrocortisone, 
as well as other 3 alpha-ol ring A saturated steroids, could be synthe-
sized in vitro by an enzyme present in liver microsomes which transferred 
glucuronic acid from UDPGA to steroids and other aglycones. 91 It was shown 
that normally 60'%. of administered hydrocortisone-4-c14 was excreted as 
92 
metabolites conjugated with glucuronic acid, because hydrocortisone. 
93 
does not have a 3 alpha-ol in ring A, it can not be conjugated directly. 
Peterson and Scbmid93 infused hydrocortisone into J.D., four normal 
subjects and three patients with liver disease (two cirrhotic and one he-
patitic). The disappearance of the metabolites, tetrahydrocortisone and 
therefore presumably hydrocortisone, from the plasma was significantly 
delayed as compared with the normal subjects and other liver disease pa-
tients. Concurrently, the appearance of the conjugated tetrahydrocor-
tisone was also slower. The total amount of glucuronic acid conjugated 
metabolites appearing in the urine after the infusion of hydrocortisone 
W.s only one half of that found in normal subjects. Similar studies of 
Childs et a12 also showed glucuronide conjugates of hydrocortisone-4-c14 
was much decreased in a patient with CFNJ,. J.D.H. Here they found that 
free hydrocortisone and its unconjugated metabolites were slightly but 
not significantly delayed in leaving the blood, while the conjugated 
metabolites were present in the blood in slightly reduced amount. They 
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also infused tetrahydrocortisone in a separate experiment into the same 
patient to eliminate the possibility that the reduction of hydrocortisone 
to tetrahydrocortisone was impaired and not the glucuronide conjugation 
system, The unconjugated compound was slightly delayed in its disappearance 
but the amount of the conjugated form in the serum was markedly lower 
as compared to that in the normal subjects. 
Thus the formation of steroid glucuronide was found to be impaired 
93 by both studies, But as Peterson and Schmid pointed out,the metabolism 
of endogenously produced biologically active steroids is apparently not 
disturbed, and the defect in steroid glucuronide formation can be demon-
strated only by administration of a loading dose of ring A reduced steroids, 
Both studies observed that the total steroid excreted in the urine in 
these patients were normal. This indicated that these patients have 
an alternative path of hydrocortisone excretion. In normal adults appro-
ximately 25% of the dose of administered hydrocortisone appears in the 
2 
urine tn an unknown form. J.D.H. had an unknown fraction greater than 
25%. 2 This may suggest that a relatively larger portion of the steroid 
metabolites was excreted as sulfates. 15 
More recently, Holman and Gol11bGiff94 reported three: .. sib1;i.ngs.with 
CFNJ. One child (I.<P.B. or Twin B) showed definite defect in glucuroni-
.J/ dation of hydrocortison and tetrahydrocortisone, in contrast to the 
earlier findings. But another child (T.J.B.) showed normal metabolism 
of tetrahydrocortisone. 
Thus the ability of CFNJ .patj.ents."to ... conjugate steroids seems less 
than normal; but the question is not yet settled. 
B. Salicylate Conjugation: Salicylate conjugation is another means 
27 
of studying the defect in conjugation of patients with CFNJ. Salicylate 
conjugation, however, has the following features. The metabolic fate of 
95,96,97 ingested salicylate has been relatively well worked out. The 
largest fraction to appear in urine is that conjugated with glycine, the 
second largest fraction with glucuronide, and the lesser fraction re-
mained unconjugated. Two kinds of salicyl glucuronide are formed: the 
98 
acyl and the phenolic types. This provides an opportunity to test the 
extent to which patients and their relatives are able to make each type, 
but also makes interpretion of results more difficult when discrepancies 
occur. 
of the 
The conjugation with glucuronic acid appears to be characteristic 
2 individual, and thus lessens fluctuations of data in any one 
individual. One of the major drawbacks, however, is that , of the admini-
stered dose, only 10-15% is excreted as glucuronides in the normal indi-
vidual. 
2 
Childs,Sidbury and Migeonc. administered sodium salicylate to J.D.H., 
M.E.H., K., and their relatives. The data showed that, depending upon 
the dose, the affected patients performed at a level of 1/6 to 1/3 that 
of the controls, indicating a matked impairment. The relatives showed 
impairment intermediate between that of the patients and the controls. 
These findings were confirmed by Holman and Goluboff in T.J.B. and her 
relatives. 94 
Childs et al also observed ~hat the patients and some of the re-
la~1Yes produced more of the acyl glucuronide than the phenolic while 
the controls produced the two glucuronides in roughly equal quantities.2 
As bilirubin is presumed to be conjugated exclusively through~its carboxyl 
groups,85,99 it was anticipated that the amounts of glucuronides formed 
by the patients would be either generally depressed, or else the 
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depression would be manifested principally in the acyl fraction, Yet 
it appears as if the phenolic fraction is depressed more than the acyl 
in the patients, while in the relatives who show any depression at all, 
it is .the phenolic fraction which is wanting, No explanation is yet 
available for this phenomenon, 
C. Conjugation of Obher Non-Bilirubin Aglycones: Other compounds 
have been used to study the conjugation in CFNJ patients. By giving, orally, 
N-acetyl-p•aminophenol (NAPA), which forms a glucuronide, it was found 
that the rate and magnitude of glucuronide formation in these patients is 
much less than in normal.100 In addition the rate of disappearance of 
the free compound from the plasma is delayed,lOO 
Later, Scbmid9 administered NAPA to three patients (J.D., J.d'E., 
R.S.) and normal subjects of the same age and sex, The concentration of 
NAPA glucuronide in the plasma was much less in the icteric child and 
the disappearance of the free compound from the plasma was delayed, The 
total recovery of NAPA was comparable to that in control subjects but 
the glucuronic acid conjugated fraction was reduced in the patients. 
Chloral hydrate and its reduced product, trichloroethanol,have also 
been used in these conjugation studies, In the body the latter compound 
is either oxidized to trichloroacetic acid or excreted as the glucuronide 
101 in urine and bile, of which only negligible amounts are in the uncon-
jugated form. In J.D.H. and his parents, the urine excretion of trichloro-
ethanol was much less than that of normal controls, after ingestion of 
either chloral hydrate or trichloroethanol, 2 Similar results were ob-
9 
tained by using menthol. Excretion of hippuric acid and of salicyluric 
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acid was found, however, to be unimpaired.lS Thus a defect in the con-
jugation of glycine can be eliminated. No work has been reported on 
the state of sulfate conjugation in these patients. 
II,, Studies on Patients, in Vitro 
In vitro studies of the liver homogenates of several patients were 
done. The liver tissue of R.S. was studied by Schmid. 9 Bilirubin and 
o-aminophenol were incubated with liver homogenates and microsomal pre-
parations, respectively. It was observed that liver homogenates failed to 
form direct reacting bilirubin, 46 but the microsomal preparations synthe-
sized o-aminophenyl glucuronide at a rate which was about one half of 
43 
that found with similar preparations of normal liver. 
The transferase activity of liver homogenates of J. was also tested 
by combining the liver homogenates with bilirubin and either rat or human 
16 liver extract containing UDPGA. No direct bilirubin was detected from 
this system. If, however, the patient's liver homogenate was substituted 
by the normal rat liver homogenate, direct bilirubin was detected. This 
implied that the patient 1 s liver homogenate was defective in glucuronyl 
transferase activity. Conjugation of o-amin0phenol was also found to 
be impaired when it was used instead of bilirubin in the above microsomal 
system. However, the authors pointed out that the bile aspirated from 
the patient's gall bladder contained only direct reacting bilirubin, which 
indicates that either the above transferase test was not sensitive enough 
or there is an alternative pathway for glucuronide formation. It can be 
pointed out again that the presence of any solubilizing substance such 
as bile acid, urea or citrate will lead to a direct diazo reaction.33 
It must also be noted that this patient was first reported as one with 
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"Gilbert's disease", 6 but later classified as a Crigler-Najjar, 9 
In vitro studies of liver tissue was also in two patients who ori-
16 ginally were believed to have "Gilbert 1 s disease", was then thought to 
have a defect similar to CFNJ.102 This controversy will be discussed in 
detail, later, In these two patients liver homogenate was found to lack 
the ability to form glucuronide both:.with bilirubin and with o-aminophenol. l6 
III. Studies on Gunn Rats 
Another valuable means of studying the CFNJ patients has been the 
103 
use of a mutant strain of Wistar rats, described by Gunn and Malloy and 
Loewenstein104• These rats are strikingly similar to hhe patients with 
CFNJ, thus providing an excellent laboratory tool for studying the etiology 
of the defect in bilirubin conjugation, BUt before I go into the results 
of work done on Gunn rats, I would like to describe them briefly, 
Gunn rats, from the time of birth, have elevated bilirubin levels 
from 5 mg/lOOml to 20 mg/100ml1 all plasma plasma bilirubin is of the 
unconjugated type, and bilirubinuria is absent. 43 Similar to patients with 
43 104 CFNJ, these rats have no evidence of increased hemolysis, ' and have 
43 
reduced fecal urobilinogen, That the jaundice is not obstructive in 
nature was shown by the rapid excretion of bromsulphalein and.:cholografin, ·: ·' 
contrast mediu, 43 Conjugated bilirubin injected intravenously is rapidly 
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and completely excreted in the bile, increasing the biliary pigment by 100%. 42, 43 
Maximal clearance for conjugated bilirubin by jaundiced rats is similar to 
45 
maximal clearance for unconjugated bilirubin by normal rats, The bile 
of the jaundiced rats contains much less bilirubin than that of normal rats 
and the small amount of pigment present is in the non-glucuronide form.43 
The defect in these rats is thought to be inherited by an autosomal recessive 
gene because breeding of non-jaundiced ittter mates, known to be carriers, 
produced 25% jaundiced offsprings, usually, 103 Rats with bilirubin levels 
exceeding 12-15 mg/lOOml showed functional impairment and central nervoas 
system pigmentation identical with kernicterus.l05,106 
A. Studies in Vitro: Liver slices and liver homogenates of Gunn 
when 
rats did not conjugate bilirubin/incubated with liver extract as a source 
of UDPG and bilirubin. 46' 107 Nor did kidney tissue incubation with bili-
107 
rubin and UDPG produce any conjugated bilirubin, These findings suggested 
that the defect in bilirubin metabolism is in part caused by impaired 
activity of glucuronyl transferase, the enzyme responsible for transfer 
of glucuronic acid from UDPG to the aglycone. Carbone and Grodsky thought 
that the finding of impair~d formation of glucuronyl transferase can be 
interpreted as (1) glucuronyl transferase activity may include several 
unknown enzymatic steps, any of which could be defective, (2) the defect 
may not be enzymatic, .bup .. may be caused instead by the presence of an 
inhibitor or absence of some co-factor? (3) defect in other enzymatic 
107 
steps further removed in the chain of glucuronide metabolism. 
Using Gunn rat liver slices, the conjugation of aminophenol was 
found to be about one half that of normal Wistar rats and about the same 
as that of heterozygous rats which were not jaundiced,46 Liver homogenate 
of Gunn rat was found to have even less aminophenol conjugation ability 
than·.liver slices43 or no conjugation at.ill. 107 
Kidney tissue studies showed that there was no conjugation of amino-
t 
43,107 phenol in the affected homozygous ra s and reduced amount of conju-
gation in non-jaundiced heterozygous rats, 43 
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That the glucuronidation is defective for both bilirubin and o-aminophenol 
led to Carbone et al's suggestion that there is an impairment of the 
mechanism of glucuronidation rather than a specific defect of the meta-
bolism of bilirubin, 107 But the question, why can the Gunn rat's liver 
tissue conjugate some aminophenols but no bilirubin at all, is not ans-
wered. 
Lathe et a146 suggested that if bilirubin and aminophenol shared the 
same process of glucuronidation, then one should be able to demonstrate 
competition for this simple process of enzymatic conjugation, They found 
that bilirubin conjugation in the normal rat was inhibited by relatively 
high concentration of o-aminophenol, but bilirubin failed to inhibit 
o-aminophenol conjugation, 46 At the same time they pointed out that 
among different animals there was no parallel between the capacities to 
conjugate the two substrates bilirubin and o-aminophenol: the cat conju-
gated bilirubin but not o•aminophenol; the rabbit conjugated o-amino-
phenol two to three times as fast as bilirubin; the homozygous Gunn rat 
conjugated o-aminophenol but not bilirubin. 46 
Studies to eliminate defects in UDIG dehydrogenase were done by 
Lathe and Schmid and their associates, 43, 46 They found that UDPG de-
hydrogenase activity was ibout equal in the liver of homozygous Gunn 
rats, their leterazygous litter mates, and normal controls. Addition of 
UDPGA to microsomal preparations of icteric rats failed to augment 
h i 43, 46, 107 glucuronide synt es s. 
Schmid et al showed that an inhibition factor in Gunn rats was not 
likely to be the etiology of the defect in glucuronide conjugation. 43 
They observed that. when equal amounts of liver microsomes from Gunn rats 
and from normal SpraqueaDawley rats were mixed, no reduction in the rate 
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. ' 
<L 
of glucuronidation of aminophenol was observed, 
rhe possibility that rapid breakdown of bilirubin glucuronide by 
beta glucuronidase and therefore leading to an accumulation of unconju-
gated bilirubin was also ruled out. Attempts to inhibit engogenous beta 
glucuronidase by addition of 10-4-lo- 3 M concentration of potassium sac-
charate failed to influence the conjugative activity in the Gunn rat 
107 liver tissue. 
». Studies in Vivo: Both ester forming aglycone, o-aminobenzoic acid, 
and ether forming aglycones such as menthol were used, Oral administra-
tion of menthol and o-aminobenzoic acid in jaundiced Gunn rats and non-
jaundiced animals showed that glucuronide conjugation in the jaundiced 
rats was much smaller thsn that in the non-jaundiced rat. 46 Similar 
results were obtained with intraperitoneal injection of sodium o-amino-
benzoate. 
Urinary excretion of glucuronic acid and glucuronides of the Gunn 
rat was about one half that of normal control rats. 46 The difference in 
the daily glucuronic acid excretion between the non-jaundiced litter mates 
and normal control rats was also statistically significant. 
An attempt was made to stimulate the activity of the glucuronide 
forming enzyme system in the Gunn rat by repeated administration of large 
v 9 
amounts of an aglyconic sybstrate other than bilirubin. Sodium o-amino-
benzoate was injected but there was not increased activity of glucuronyl 
r, 
transferase as compared with non-stimulated jaundiced rats. In the sti-
( 
mrlated rats, the liver showed very concentrated amounts of o-amino-
benzoate twenty hours after the last injections, whereas non-icteric rats 
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conjugated and removed it within a few hours,9 These findings corro-
borated the fact that as bilirubin increased in the serum in jaundiced 
rats, there is no stimul9tion of bilirubin glucuronidation, 
IV, Summary of Studies on Etiology of CFNJ: 
The available evidence concerning the pathogenesis of CFNJ has just been 
reviewed. That this disease is not caused by a defect in the bilirubin trans-
port, i,e, binding to plasma protein and transfer from plasma to conjugation 
site, uptake and excretion is supported by the following findings: (1) con-
jugated bilirubin is eliminated rapidly and completely;42,43(2) maximal clear-
ance of conjugated bilirubin in Gunn rats is comparable to that of unconjugated 
bilirubin in normal rats;45(3) unpublished work of Schmid78 showed that conju-
gated bilirubin is taken up by the Gunn rat liver; (4) bilirubin is found in 
the bile of all six patients measured5,9,l5,l6 and in Gunn rats;43(5) the dia-
gnostic pattern of initial fall and subsequent sustained rise of injected brom-
sulphalein and unconjugated bilirubin, seen in defects of hepatic excretion 
but normal conjugation, is not found in patients with CFNJ. Defects in the 
transport, hepatic uptake or excretion, per se, of unconjugated bilirubin have 
not been definitely eliminated. The only finding here is that indirect bili-
rubin is found in the bile of five patients.5,9,l5 
That most of the evidence point to a defect in the biosynthesis of 
bilirubin glucuronide and more specifically, the enzymatic glucuronida-
tion of bilirubin, has already been pointed out by the review of the clinical 
and laboratory findings on patients with the disease and by analogy of findings 
in the Ounn rats. 
The defect in the enzymatic conjugation of bilirubin with glucuronide 
has been sought along the following lines: (1) enzymatic steps leading to 
the production of UDPGA; (2) enzymatic step involving glucuronyl transferase 
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leading to formation of bilirubin glucuronide; (3) inhibition on the 
enzymatic system resulting. in failure of conjugation; (4) deconjugation 
of conjugated bilirubin in liver ~ell or canaliculi; (5) non-glucuronide 
conjugation systems (sulfate, glycine, etc.). I shall eliminate those 
factors which seem unlikely in the light of the evidence presented. 
The enzymatic steps prior to that involving glucuronyl transferase 
can be temporarily ruled out on the following basis. It was found that 
UDPG dehydrogenase activity was normal and failure of glucuronide con-
4~~1W jugation was not due to insufficient glucuronic acid. This 
favors a defect in an enzymatic step after UDPG dehydrogenase, but does 
not eliminate a defect in previous steps, in the presence of a defect in 
glucuronyl transferase. One would expect, however, that any defect prior 
to or directly involving the formation of UDPGA will lead to symptoms due 
to defects in normal metabolic processes dependent on UDPGA or its pre-
cursors. Thus one would expect some manifestation of symptams of galac-
tosemia and lack of chondroitin sulfate. Such manifestations have not 
been reported in patients with CFNJ. It is interesting to notehere, that 
108 
in patients with galactosemia, jaundice is a common occurrence. 
Failure of conjugation due to enzymatic inhibition has been ruled out 
by the findings of Schmid et al showing that when Gunn rat liver was 
mixed with normal liver, the normal liver maintained the ability to 
43 
conjugate biliru~in. 
Deconjugation of conjugated bilirubin can be ruled out because, as 
was mentioned earlier, intravenously administered conjugated bilirubin was 
excreted rapidly by Gunn rats, 42, 43 and more specifically, beta glucu-
ronidase in the Gunn rat livers was shown not to breakdown conjugated 
36 
bilirubin,l07 
.. :: A' concolll!lt'\ant defect of conjugation of bilirubin by sulfate, 
glycine and methyl radicals, along with glucuro.nidation defect, may give 
the picture of the severly elevated serum unconjugated bilirubin levels 
seen in CFNJ patients, Glycine defect has been eliminated. 15 Although 
assays on sulfate conjugation have not been reported, in view of the 
total excretion of administered steroids in CFNJ, ,·iti.has been said that a 
larger portion of steroid metabolites was, in fact, excreted as sulfate 
43 
under these conditions. The significance of methyl conjugation in hili-
rubin excretion is, at best, very·:sihall, Thus' it seems unlikely to .expect 
any concomittant defect in non-glucuronide conjugation to be an important 
factor for consideration, 
These above considerations, then, leave\ one with the most likely 
defect of, this disease: that of the enzymatic step involving glucuronyl 
transferase leading to formation of bilirubin glucuronide. The evidence 
supporting this has been presented, and~~-~ there is no 
evidence to the contrary. Before anything definite can be said regarding 
the etiod;pgy of CFNJ, however, more work need be done in some of the 
areas of uncertainty to which I have alluded. 
v,. Related Problems 
A. Alternative Pathway for Bilirubin Metabolism in CFNJ: Patients 
with CFNJ maintain a remarkably constant serum bilirubin level, despite 
their defective glucuronidation. It can thus be presumed that an alter-
native pathway for bilirubin excretion exists, although the finding that 
5 9 16 direct reacting bilirubin has been noted in the bile of three patients 1 1 
and to a very small extent in serum leads to the possibility that 
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glucuronidation, though defective, does occur to some extent, in vivo. 
Alternate pathways of bilirubin excretion would include conjugation with 
sulfate, glycine, and carboxyl-linked methy1. 64 These pathways are favored 
by the findings that ultimate total excretion of injected steroids are 
undiminished in CFNJ,lS and that hippurate excretion following given dose 
of benzoate was greater in Gunn rats than in normal rats,43 thus making 
the compensatory loading of these alternate conjugation routes very sug-
43 gestive. Moreover, recent studies on amphibia showed that biliary ex-
cretion of bile pigment was independent of the presence of functioning 
76 
mechanism for glucuronide formation. 
Bilirubin may be excreted without conjugation, since indirect hili-
rubin is found in the bile of five patients5' 9' lS. 
43 
rats. 
and in that of Gunn 
One of the most likely pathways of elimination is apparent from the 
recent studies on gastrointestinal excretion of unconjugated bilirubin, 
mentioned earlier. That extrahepatic sites may be involved in the con-
jugatton ann elimination of bilirubin is also supported by earlier findings 
97 
on extrahepatic conjugation of salicylate. 
Other possible alternatives of bilirubin excretion are based on the 
finding that urobilinogen recovered in urine and feces of normal man 
falls far short of that expected from h~globin degradation. The possibi-
lities of this discrepancy have been sought in terms of (1) degradation 
of urobilinogen to dipyrrl-methenes, such as mesobilifuscin,(2) reabsorp-
t!lon of urobilinogen from intestinal tract and re-utilization in porphyrin 
synthesis, (3) destruction of reabsorbed urobilinogen in liver, (4) an 
alternative pathway for hemoglobin degradation to colorless compounds not 
40 
coupling with diazotized sulfanilic acid. The first three hypotheses 
38 
109 110 have since been refuted, 1 and there is no direct evidence reported 
to support the last contention. 40 
B. The Specificity of Glucuronyl Transferase: The findings that the 
glucuronidation of some compounds are more affected than others, eg. Gunn 
rats did not conjugate bilirubin at all1 but were able to conjugate some 
o-aminophenol1 sugg~sts that perhaps there are different transferase 
systems for different compounds. It was noted in normal rats that although 
o-aminophenol inhibited bilirubin excretion, the inhibition was not 
competitive. 89 Moreover, bilirubin did not inhibit o-aminophenol. There 
were also no parallel capacities of bilirubin and o-aminophenol conjugation 
in different animals. 89 Another study showed that infusion of NAPA did 
not decrease bilirubin conjugation in vivo. 42 Ruptured cell preparations 
had a markedly different effect on the conjugation systems. In rat and 
mouse, bilirubin conjugation was increased by using ruptured cells, but 
in these and other animals, breaking up the cells had a depressing effect 
on o-aminophenol conjugation.46 
The findings of Dutton and Axelrod et al suggest that a simple 
enzyme catalyzes the 
carboxylic and amino 
time when a compound 
operations of steric 
transfer of glucuronic acid to phenolic, alcoholic,, 
42,111 
acceptors. It has been suggested that the 
is not conjugated with glucuronide may be due to 
91 
factors. Thus cortisone is not conjugated, whereas 
112 
tetrahydrocortisone and testosterone are. Also it is noted that the 
latter steroids have the same beta configuration as naturally occurring 
111 107 glucuronides. Furthermore, Carbone and Grodsky observed that 
borneol, which is conjugated by the body only as a glucuronide, competitively 
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inhibited bilirubin glucuronide formation in vitro. This finding further 
favors a single enzyme in the transfer of glucuronic acid. 
Studies on the Gunn rat and patients with CFNJ also showed that 
the enzymatic defect in glucuronide formation not only involv~ synthesis 
of bilirubin glucuronide but also includes glucuronidation of a variety 
of compounds. This can also be interpreted as evidence for one enzyme 
in glucuronidation. It is noted that these same findings have been used 
to support the contention of multiple enzyme system. 
The current viewpoint seems to favor a single enzyme for glucuron~ma-
tion of bilirubin and non-bilirubin aglycones, since no other enzyme has 
been demonstrated. A definitive answer, however, must await the purifi-
cation of the enzyme, glucuronyl transferase. 
Furthermore, it has been suggested that the conjugation of non-bilirubin 
compounds occurs primarily outside the liver and thus fait to reflect a 
possible defect in bilirubin glucuronidation. 102 
40 
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G~NETIC CONSIDERATIONS 
Familial involvement is an unquestionable feature of patients with 
this disease ( see 'ftblolt- II ) • All,except rt.ve of the reported cases, have 
one or more members of the family group affected by the same disease. In 
three of the fi'Vlor cases ( J.,J.d 11i:.,W. ) without reported famili.al involve-
ment, the following observations are notable. The paternity of J. and her 
siblings are doubtful because of the obvious sexual promiscuity of her mother,6 
The brother:· of J. d 1 E. 1 s father was noted to have "Gilbert 1 s disease", 
questionably of hepatitic ··orig}.n, total serum bilirubin 2mg% and indirect 
bilirubin 1.7 mg%. 11 w. is the first Negro child reported to have this 
disease.5 Unfortunately, there is no available data on the family history of 
R.s •• 9 Consanguinity was noted in one family group only. 1• 2 ln all, except 
the case of a negro child, the patients were Cauca-silml!; and Italian parentage 
was noted in two family groups J.D.,R. and J. d 1 ~ •• 
The familial aspects of this disease suggested that it was genetically 
determined and the aggregations of patients solely in sibships, never 
involving parents, suggested that the affected children are homozygous 
possessors of an abnormal Mendelian recessive trait. 1 • 2 From the cases with 
clear family history, which includes all family groups excepting w .. J.HP, 
J .H~, R.S. ,and K.; the ratio of affected children to non affected siblings 
is 16/50 or 32%. This ratio is not very far from the mode of inheritance of 
a recessive gene. The number of reported cases are perhaps tooTew, however, 
to permit any definitive genetic studies at this time. 
Careful geneological investigation has been mostly confined to the 
·.''l 
·• 
•I;. 
) 
TABLE 
Patients Rela- No. of Total Total Family 
tion- Patients No. of No. of Group 
ship of in Child- Family Members 
Patients Family ren in Group* Probably 
Llf 
JRH,JDH Sibs 
XXH 
JLT,LT Sibs 
JJT 
MEH' 
Cl) 
r-1 
,g. 
(I) 0 
~0 
Cl) 
58 
..... 
~~ 
Cl) ... 
~:~ ... 
Cl) ~ ~~ 
>OU 
JD 
R 
Double 
First 
Cousins 
J 
K 
WJH~JH11 Sibs 
RS 
Jd 1E 
1 
3 
3 
1 
1 
1 
1 
1 
2 
1 
1 
Family Members Affected 
3 
5 
14 
3 
3 
2 
8 
J' 
2 
Inves- b,y Hist-
tigated ory Only 
5o¢ rl5 H 
1 9 -
10 ? 
r-
5 
*** 
w 1 7 - 0 
) 
II 
Heterozygotes as Deter- Total No. of 
mined b,y Glucuronide Heterozygotes in 
~retion Tests: Family Group/ 
Sibs Parents All Other No. Tested in 
=---~~~--~~R~el=a7t~i~v~e~s Family Group No. of Heterozygotes 
No. Tested 
0/2 
3/6 
0/1 
-lzr 
2/2 
1/2 
2/2 
2/2 
-/2 
0/2 
0/2 
10/18 
8/14 
6/10 
8/15 
2/2 
-/2 
10/18 s 
10/18 s 
10/18 s 
10/18 s 
2/2 N 
2/2 N 
-/6+ s 
0/2 N 
0/2 N 
RMB,RPB Twins 3 3 - 0 - 1/2 + 1/2 S 
TJB Sib 
*Family Group includes Immediate Family and All Other Relatives;**Brother died few hours after 
birth, of atelectasis;***Father 1 s Brother has 11Gilbert 1s Disease";S,N means Family Members 
tested by Salicylate Excretion and NAPA and p-Aminophenol Excretion, respectively;(-) means 
data not availableJ H means information obtained by medical family history only. 
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large family group described by the original authors of this disease.l 
Eight patients from four related families, M.,T.,H.,H•., were the sixth 
generation descendents of one couple M •• The family pedigree of these 
patients, including 505 individuals, showed fifteen probably affected 
individuals,1 Since the specific criteria~used to determine whether 
any member was 11probably affected,~" were not described, these fifteen 
individuals were probably discovered from the medical fami~ history. Serum 
bilirubin concentration of parents and nonaffected siblings were consistently 
normal.l,2 
Assucoing that glucuronide formation was defective in these patients, 
Childs et al fed sodium salicylate to eighteen family members ( parents, 
nonaffected siblings and grandparents ) of related families T.,H.,and H'. 
and estimated the excretion of salicyl glucuronides and of other salicylate 
metabolites in urine2• In five out of the six parents, a reduction in 
glucuronide excretion was demonstrated. In three out of nine nonaffected 
siblings tested, one grandparent, and one great-grandparent, similar find-
ings were noted. This gave a total of ten, out of eighteen, family members 
tested who showed reduction of salicyl glucuronide excretion. 
From these findings, Childs et al postulated that the defect was due to 
an abnormal gene, recessive with respect to bilirubin, but incompletely 
dominant for other glucuronide forming coupounds. 2 
The parents of J.D., J.d 1E. and R.S. were studied by intravenous 
injection of NAPA followed b,y estimation of NAPA glucuronide and total 
aminophenol excreted in the urine9. Only two of the six parents showed 
reduction in glucuronide excretion. 
Another study, measuring salicylate conjugation in parents and family 
4J 
members of R.M.B., R.P.B., and T.J.B. revealed a number of persons who 
were suspected of being hetero~gotic, one parent definitely hetero~gotic 
and the other parent probablY hetero~gotic also94. 
It is noted, however, that the significance of such family studies is 
limited by the existing uncertainty with regard to the exact pathogenesis 
of this disease and by the fact that the extent to which glucuronidation of 
nonbilirubin aglycones are depressed in this disease is unsettled. 
' 
·\ 
CFNJ Vl!JISUS 11GILBI!:RT'S DlS.I!JISJi;" 
The stmUilrity between CFNJ aDd "Gilbert's disease" was first noted 
by Crigler and Najjar. 1 It has even been suggested that the two disease 
entities may represent different degrees of the same defect.lS,ll4,ll5 
The entity of "Gilbert's disease" is still not clearly defined. If the 
term is used to include all instances of unconjugated hyperbilirubinemia 
not due to overt hemolysis, which has been considered reasonable in view 
of the ill-defined nature of Gilbert's original cases, the entity may 
include (l) the Crigler-Najjar syndrome, {2) the hyperbilirubinemias seen 
following viral hepatitis and in associated with other diseases of the 
hepatobiliary system, caused probably by a defect in the transport mechan-
ism of the hepatic parenchymal cells, {3) compensated hemolytic diseases 
with probable additional defect in bilirubin transport or hyperplastic 
bone marrow overproduction of bilirubin. 40 Most of Gilbert's cases probably 
suffered from the last category. 9 
The overall features of the "Gilbert's syndrome", however, can be 
distinguished from that of the Crigler-Najjar syndrome. 1 The former is 
usually a mild, chronic, 
rubinemia. The question 
apprently non-hemolytic, unconjugated hyperbili-
9,40 
of familial involvement is not sett~ed, 
1 
while familial involvement is the rule in the Crigler-Najjar patients. 
Onset is usually in late childhood or early adult life, although cases 
occurring in infancy and later life have been described. The serum bili-
rubin concentration tends to be 15-25 mg/lOOml lower than that in the 
Crigler-Najjar infants and usually less than 5 mg/lOOml. The patients 
are often asymptomatic and jaundice is discovered during some unrelated 
45 
illness or during a routine physical examination, although fatigability, 
asthenia, and gastrointestinal COJiillaints are reported, Laboratory find-
ings on liver function tests are normal, except for prolonged bilirubin 
retention, Histologically the liver shows no significant abnormality, 
Erythrocyte survival time has been found to be slightly reduced, but the 
reduction is far too little to account for the hyperbilirubinemia,40 On 
chromatographic analysis, serum pigment was identified as unconjugated 
bilirubin, but pigments I and II have been found in bile, the latter pre-
dominating,l6,115 
There has been some controversy over two patients reported b,y Arias 
and London,l6 with serum bilirubin levels of 8,8 and 18.8 mg/lOOml, res-
pectively, The high serum bilirubin levels suggest that these are probably 
examples of "Gilbert's syndrome" as a consequence of deficiency of glucuronyl 
transferase in liver. 16 These authors in collaboration with Lowy, sub-
sequently confirmed their contention in six similar patients with serum 
bilirubin levels ranging from 1,8 to 22.0 mg/lOOml, 62 using the conju-
gation of 4-methyl umbelliferone with glucuronide by homogenates of liver 
needle biopsy specimens as index of glucuronyl transferase activity, 
Later studies, however, were not able to demonstrate any defect in the in 
vivo conjugation of N-acetyl-p-aminophenol (NAPA) and menthol with glu-
curonide in patients with relatively low levels of serum bilirubin. 102•115 
Schmid et al concluded that the defect in "Gilbert's syndrome" is not a 
deficiency of glucuronyl transferase, but may involve a faulty mechanism 
for bilirubin transport from plasma to the enzyme conjugation site in the 
liver ce11. 102 Schiff and Billing supported this viewpoint, but they 
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pointed out that in vivo tests with ethereal forming glucuronide re-
ceptors, such as NAPA and menthol, may not be a valid measure of bili-
rubin glucuronyl transferase activity, since the latter entails the 
formation of an ester glucuronide. 116 Arias has subsequently attempted 
to resolve these conflicting viewpoints by suggesting that the contro-
versial patients may have a non-lethal variant of the Crigler-Najjar 
syndrome without kernicterus and that this entity is included in the 
heterogeneous group of "Gilbert's syndrome".ll7 
There has also been some confusion regarding J. She was first 
studied16 and reported6 as a patient with "Gilbert's disease". Her high 
serum bilirubin level, 16-22 mg/lOOml, early onset of jaundice and kern-
icterus, severity of central nervous system disturbances, and normal 
erythrocyt:_f'~a.gj,J:i:I:.Y test, however, all point to the Crigler-Najjar 
syridrome or CFNJ. She has, therefore, been considered as a patient with 
the latter syndrome.9 
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PREVENTION OF KERNICTERUS 
The majority of the patients died of kernicterus during the neonatal 
period and the patients who survived this period usually developed signs 
of central nervous system involvement during their early childhood. A few 
have not developed any signs of central nervous system damage (J.~.•t, M.~.H. 
J.D.H.)despite continuously elevated levels of indirect bilirubin around 
20 mg/lOOml, but they are in constant danger of developing signs of central 
nervous system involvement. 
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It is thus c•evident that the main symptoms of the CFNJ patients are 
jaundice and central nervous system disturbances, consistent with kernicterus. 
Although kernicterus is a complex problem and requires a paper of its ow, 
I would like to discuss it very briefly because of its importance as the 
only outstanding complication of the CFNJ disease. Moreover, why these few 
children have survived without the development of the full syndrome of 
kernicterus is still a ~stery. The care and treatment of the CFNJ patients 
is•the prevention of kernicterus. Therefore I will limit the discussion to 
only this aspect of kernicterus. 
!.Factors Which Increase the Occurrence of Kernicterus: 
In order to prevent kernicterus one must know the factors which 
influence and precipitate it. These factors can be divided into three 
catagories: l) Those which increase the total body bilirubin; 2) Those 
which cause bilirubin to move into the tissue, especially the brain; 
3) Those which increqse the susceptibility of the brain cell to the effects 
of bilirubin. 
Among the factors which increase total body bilirubin are: l) increased 
hemolysis of erythrocytes) 2) large doses of vitamin K (Here the mechanism 
is still much debated.)t18-123 3) absorption of hematoma; 124 4) liver 
damage due to anoxia. 125-127 
Factors which affec~ movement of bilirubin into the tissues are: 
l) the quantity of serum albumin;JJJJ7 2) drugs such as sulfisoxazole and 
salicylates as well as endogenous substances such as hematin, as mentioned 
earlier, and nonesterified fatty acids, (These have been shown to compete 
with bilirubin for albumin binding sites.); 129-l33 )}alterations in pH 
which affects albumin binding of bilirubin; 34•13;4J'presence of competing 
anions. 25 
Factors which affect the susceptibility of the brain cell to the effects 
of bilirubin are:l) the intrinsic susceptibility of the cell, especially 
the basalganglion cells;134,l35 2)the metabolic demands on the cell and 
therefore the extent to which a cell can continue to function when the basic 
process of oxidative phosphorylation is iJ143aired1 7l 3) prior damage to brain 
cells b,r hypoxia; 126,l36 4) functional maturity of the blood brain barrier; 25 
5) prematurity of the patient,137 ,l38(Adult animal seem better able than 
newborn animal to withstand hyperbilirubinemia. 105,l39); 6) infection and 
trauma,71( moribondi state of cell tend to t~~e up more bili~bin:f13 ~ 
'"""'~ ,./ v Knowing thesb precipitating factors will help us fin trying to prevent (i" ·..,.. 
\;' f VII I 
thj'occurrenc~~ each in the patient~However, Dr.G.~~llichap15 observed 
that the purer the bilirubin, the smaller the effect on the depression 
of oxygen consumption on brain slices. Thu~human kernicterus can not be 
explained as a single sequalae of bilirubineaia. Also Nores "et all40 believed 
that hyperbilirubinemia wit~ut iso-immunization does not involve risk of 
brain damage to healthy full term infants. They found no evidence of 
5o 
any cerebral lesions,irrespective of exchange transfusion or not in the 
absence of hemolytic disease and in full term vigorous infants. Thus it 
seems that the factors affecting kernicterus is more complicated than those 
mentioned above. 
!!.Therapeutic Measures: 
Various therapeutic measures have been tried to treat hyperbilirubinemia, 
all of which are based on maneuvers which decrease the extracellular bilirubim 
levels and prevent movement of bilirubin into cells. 
Exchange transfusion is the o~ accepted method of treating hyperbili-
rubinemia. It removes the albumin bound bi~irubin from the circulation and 
reduces the tissue bilirubin as equilibration takes place between the tissue 
and the circulation.141 Bilirubin is not dialyzable because it is bound to 
albumin. 126•142-144 In CFNJ patients,J01D•H•aniil L.'l:., however," exchange 
transfusion produced lowering of the serum bilirubin for less than 24 hours 
and is therefore therapeutically of little value. 1 
The evidence on the effectiveness of albumin as a means of treating 
hyperbilirubinemia has been contr~dictory. Johnson has shown that when 
parenteral albumin was given to Gunn rats, the serum bilirubin rose but 
kernicterus occurred in only 20% compared with the expected 5o-6o%.145 
Protection was less sure when infection was present. 145 Bowen et all46 
showed that puppies were protected from a toxic dose of bilirubin by 
simultaneous injection of albumin. Rosdilskyf47 however, found that when 
he injected bilirubin-albumin solutions intravenously into rats, rabbits 
plasma 
or dogs, highAbilirubin levels resulted and three of the 51 animals used 
died in shock with in 24 hours. Apparently bilirubin may still be toxic 
even when attached to albumin. There has also been some work done to show 
that when albumin is given along with an exchange transfusion the am:>unt 
of bilirubin removed is increased.l30,l4B-l50 In the face of these contra-
dictory findings, it is difficult to recommend albumin for treatment of 
hyperbilirubinemia, especially since there is the danger of precipitating 
heart failure in the loading of albumin. 
Steriod treatment is advocated b,y some,l5l but no systematic studies 
have yet been done to prove its usefulness. ·Adequate trials of ACTH in 
J.D.H. and L.T. produced neither significant changes in the patients nor 
in their jaundice.1 
Cremer et all5la have recommended blue light exposure as treatment 
because it may decrease: as much as 30% of bilirubin levels in vitro. It is 
also true that J.d1E. 1s jaundice is noticably less in the summer.ll However 
clinical trials have had contradicting results. Those by Blondheim et a1!52 
and Franklin153 showed no significant effects, whereas those b,y Ferreira 
et al;~Howed favorable results. This form of treatment needs also further 
investigation because of the fear that bilirubin msy be converted into an 
51 
even more dangerous substance.153 Blondheim et al155 suggest a more diffusable 
"bilirubinoid" might be produced which has some of the properties of 
dissociated bilirubin and therefore potentiallY more dangerous than ~bUDin 
bound blirirubin. Thus the use of ultra-violet light is an interesting but 
questionable method of treatment. 
The use of glucuronic acid has been much debated.l56-l5B because the 
intra-
role of glucuronic acid ~atic or extrahepatic bilirubin conjugation is 
still under investigation as discussed in section under Review of Bilirubin 
Metabolism. The results of in vivo administration of glucuronic acid, however 
hai~ot been encouraging. Infants with unconjugated hyperbilirubinemia due 
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to erythroblastosis or physiologic jaundice were found to have lowering of 
serum bilirubin level when glucuronic acid was infUsed.l59 These findings 
were confirmed b.1 experiments in the Gunn rats, but it was further noted 
that the drop in serum bilirubin did not prevent kernicterus and was usually 
accompanied b.r increased icterus of bo~ fat. 160 These latter findings 
suggested that the fall of serum bilirubin observed, might be attributable 
work 
to a shift of pigment to the tissues, especially in the light of present;on--
the total miscible bilirubin pool which indicate that it is five to six 
52 
times plasma bilirubin content. 26 Moreover, Hsia61 found no evidence of 
conjugation when glucuronic acid was administered to dogs; and Schwob· et al161 
retracted their claims for the therapeutic value of glucuronic acid because 
they have obtained similar effects for intravenous infusion of glucose-saline. 
Other attempts to activate glucuronide conjugating activity by using 
anthranilate, 162 and N-acetyl-p-aminophenol163 have been unsuccessful. 
Triiodothyronine has also been tried but the effect was insufficient to be 
. 164 165 
of therapeut~c value. ' 
In the light of the recent studies on the absorption and excretion of 
bilirubin in the gastrointestinal tract, mentioned earlier, a possib~ new 
method to treat hyperbilirubinemia of indirect type may be base~on the binding 
of the unconjugated bilirubin excreted into the gut. 77 If unconjugated 
bilirubin was removed in the gut from the equilibrium established between 
the bilirubin pool of the gut and that of the plasma, then plasma bilirubin 
would move continuously into the gut, until another equilibrium is established. 
A resin cholestyramine, which was found to exhibit a high affinity for 
bilirubin was given orally to Gunn rats b,r Lester, Hammaker,and Schmid?7 
Serum bilirubin concentration decreased abruptly and returned to pretreatment 
levels on withdrawal of the resin. Similar studies were done on a CFNJ 
• 
patient,J.d1 E •• So far the resultsdid not indicate that the resin lowered 
the patiilnt 1s bilirubin level significantly. 78 f,lore·extens•ive studies 
' 78 
are planned in this same patient, ·and in others. 
Thus it is evident that at the present there is no recommendable 
treatment for patients with this disease, except for prophylactic measures 
to prevent · the occilrrenoe of kernicterusC:4 1 ) 
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